ZappRx is a Boston-based digital health company that streamlines specialty medication prescribing. Its platform collects and maintains pharmacy information, payer/prior-authorization requirements, and relevant clinical history, enabling providers, pharmacists, and payers to digitally interact to fill prescriptions and reduce faxes and phone calls. The platform is currently live in Pulmonary (including Cystic Fibrosis, Pulmonary Arterial Hypertension, and Idiopathic Pulmonary Fibrosis), Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn’s Disease and Ulcerative Colitis). As the company grows, ZappRx plans to expand into Rheumatology, Neurology, Oncology, and other rare diseases. CureDuchenne has invested in the ZappRx platform to add Duchenne muscular dystrophy to the platform in 2019. ZappRx emphasizes collaboration with organizations like CureDuchenne to improve treatment access for patients with rare diseases. ZappRx provides a platform that automates specialty prescription processing in real time, aiming to remove manual fax- and phone-based workflows that delay prescriptions and cause errors. Its app is already used in several top academic medical centers and multi-specialty practices in the U.S. The company targets conditions such as oncology and pulmonology where prescription coordination is complex. With new funding, ZappRx plans to expand further into the U.S. drug prescription market, hire engineers and business development managers, and forge partnerships with specialty pharmacies. The team describes a goal of creating a one-click, price-optimized drug purchase experience akin to “Kayak meets Amazon.” The article cites a fast-growing market opportunity worth as much as $400 billion in the next few years and states total funding to date is $41 million. ZappRx provides an app-based prescription data automation platform that sends prescription information in real time between doctors and pharmacies, aiming to eliminate fax and phone workflows. The company shifted its focus from a broad consumer goal to specialty pharmacies that serve patients with acute or chronic conditions, where the need for specialty medication coordination is greater. ZappRx’s platform is intended to ensure specialty patients receive medications reliably by automating communications and reducing lost or missing faxed prescriptions. The Series A financing will be used to further build the prescription data automation technology and to scale operations. Following the round the company recently hired 17 people and plans to hire an additional 15 in the near term. To date ZappRx has raised $8.8 million in total funding. ZappRx offers a HIPAA-compliant, pharmacy-agnostic mobile platform that lets patients check out prescriptions, enables pharmacies to pre-process orders, and gives doctors visibility into pickup and fulfillment. The app is designed to work across multiple pharmacy chains so consumers need a single app rather than proprietary systems. ZappRx emphasizes security and user control of medical data, avoiding ads and promotions beside health information. The platform aims to reduce phone- and fax-driven inefficiencies in pharmacy workflows and shorten customer wait times. The company estimates current pharmacy inefficiencies cost drug stores about $1.2 billion annually and is working to secure revenue-generating partnerships with major chains. ZappRx has added industry advisors to support growth and commercial deals. ZappRX is a mobile app and digital-prescription service that functions like a "boarding pass" for the pharmacy, allowing patients to bypass checkout by showing a digital prescription. Patients can download the app, add payment and insurance information, and doctors can create and securely send prescriptions and notify the nearest pharmacy to begin processing. The app is in beta testing in New York with two doctors at New York‑Presbyterian/Weill Cornell and the independent Zitomer Pharmacy. Features include smartphone medication reminders that patients or family members can set, and notifications to doctors when orders are fulfilled; the product is intended to reduce human error at pickup. Founder Zoe Barry raised $160,000 in 2012 from friends and family to hire a small team to build the app. The immediate focus is marketing, user experience testing, and getting ZappRX into the hands of doctors and patients, with a potential future revenue stream from selling de‑identified medication and patient-experience data.

Total raised

$32M

Funding rounds

5

Latest round

Series B

Latest activity

Apr 2017